{
    "eid": "2-s2.0-85115202918",
    "title": "Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis",
    "cover-date": "2021-11-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "anticoagulation",
        "cancer-associated thrombosis",
        "low-molecular-weight heparin",
        "venous thromboembolism",
        "warfarin"
    ],
    "authors": [
        "Thita Chiasakul",
        "Robert Redd",
        "Rushad Patell",
        "Adeel M. Khan",
        "Ellen P. McCarthy",
        "Donna Neuberg",
        "Jeffrey I. Zwicker"
    ],
    "citedby-count": 7,
    "ref-count": 41,
    "ref-list": [
        "Epidemiology of venous thromboembolism",
        "Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial",
        "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer",
        "American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer",
        "Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014",
        "Management of venous thromboembolism in cancer patients: ESMO clinical recommendations",
        "Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines",
        "International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer",
        "Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy",
        "Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer",
        "Updated overview of the SEER-medicare data: enhanced content and applications",
        "Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States",
        "Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser comorbidity index",
        "Comparison of different comorbidity measures for use with administrative data in predicting short- and long-term mortality",
        "Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer",
        "Prostate cancer-specific survival among warfarin users in the Finnish randomized study of screening for prostate cancer",
        "Patient education level as a predictor of survival in lung cancer clinical trials",
        "Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950\u20132014: over six decades of changing patterns and widening inequalities",
        "Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study",
        "Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis",
        "Duration of anticoagulant therapy and VTE recurrence in patients with cancer",
        "Procoagulant activity of the MC28 fibrosarcoma cell line in vitro and in vivo",
        "Warfarin inhibition of metastasis: the role of anticoagulation",
        "A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases",
        "Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75",
        "A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the cancer and leukemia group B",
        "Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a cancer and leukemia group B study",
        "Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer",
        "Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism",
        "Thrombin signaling promotes pancreatic adenocarcinoma through PAR-1-dependent immune evasion",
        "Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation",
        "Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis",
        "Thrombin drives tumorigenesis in colitis-associated colon cancer",
        "Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial",
        "The effect of Warfarin and factor VII on tissue procoagulant activity and pulmonary seeding",
        "Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis",
        "Gas6/MerTK signaling is negatively regulated by NF-\u03baB and supports lung carcinogenesis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Boston",
            "@id": "60002746",
            "affilname": "Harvard Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60014334",
            "affilname": "Dana-Farber Cancer Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60014334",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Daiichi",
        "National Cancer Institute's Surveillance, Epidemiology and End Results Program",
        "National Heart, Lung, and Blood Institute CLOT Consortium",
        "Office of Research, Development and Information",
        "National Cancer Institute",
        "California Department of Public Health"
    ]
}